Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice  Ayalew Tefferi, MD, Tiziano Barbui, MD  Mayo Clinic Proceedings  Volume 90, Issue 9, Pages 1283-1293 (September 2015) DOI: 10.1016/j.mayocp.2015.05.014 Copyright © 2015 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 1 The 2008 World Health Organization classification of chronic myeloid malignancies and mutational frequencies seen in specific disorders. Mayo Clinic Proceedings 2015 90, 1283-1293DOI: (10.1016/j.mayocp.2015.05.014) Copyright © 2015 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 2 Diagnostic algorithm for polycythemia vera and essential thrombocythemia. MPN = myeloproliferative neoplasm; + = positive; − = negative. Mayo Clinic Proceedings 2015 90, 1283-1293DOI: (10.1016/j.mayocp.2015.05.014) Copyright © 2015 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 3 Contemporary treatment algorithm for polycythemia vera and essential thrombocythemia. Aspirin is used in the absence of treatment contraindications including clinically important acquired von Willebrand syndrome. We recommend measurement of ristocetin cofactor activity in patients with more than 1 million platelets per microliter and withholding aspirin if the activity level is below 20%. Mayo Clinic Proceedings 2015 90, 1283-1293DOI: (10.1016/j.mayocp.2015.05.014) Copyright © 2015 Mayo Foundation for Medical Education and Research Terms and Conditions